2-三甲基锡乙炔嘧啶 | 193631-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-三甲基锡乙炔嘧啶
• 英文名称: 2-(trimethylsilylethynyl)pyrimidine
• 英文别名: 2-[2-(trimethylsilyl)ethynyl]pyrimidine；2-((Trimethylsilyl)ethynyl)pyrimidine；trimethyl(2-pyrimidin-2-ylethynyl)silane
• CAS: 193631-86-6
• 化学式: C₉H₁₂N₂Si
• 分子量: 176.293
• InChiKey: ZMZRIHWNMOJBLC-UHFFFAOYSA-N

物化性质

• 沸点：
  241.5±23.0 °C(Predicted)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.71
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-三甲基锡乙炔嘧啶 在 四丁基氟化铵 、 sodium methylate 、 copper(II) sulfate 、 sodium ascorbate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 叔丁醇 为溶剂， 反应 0.75h， 生成 1-(2'-acetamido-2'-deoxy-β-D-glucopyranosyl)-4-(2-pyrimidyl)-1,2,3-triazole
  参考文献：
  名称：

  Design and synthesis of O-GlcNAcase inhibitors via ‘click chemistry’ and biological evaluations

  摘要：

  Protein O-GlcNAcylation has been shown to play an important role in a number of biological processes, including regulation of the cell cycle, DNA transcription and translation, signal transduction, and protein degradation. O-GlcNAcase (OGA) is responsible for the removal of O-linked beta-N-acetylglucosamine (O-GlcNAc) from serine or threonine residues, and thus plays a key role in O-GlcNAc metabolism. Potent OGA inhibitors are useful tools for studying the cellular processes of O-GlcNAc, and may be developed as drugs for the treatment neurodegenerative diseases. In this study, Cu(I)-catalyzed 'Click' cycloaddition reactions between glycosyl azides and alkynes were exploited to generate inhibitory candidates of OGA. Enzymatic kinetic screening revealed that compound 7 was a potent competitive inhibitor of human O-GlcNAcase (K(i) = 185.6 mu M). Molecular docking simulations of compound 7 into CpOGA (Clostridium perfringens OGA) suggested that strong pi-pi stacking interaction between the compound and W490 considerably contributed to improving the inhibitory activity. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2011.03.026
• 作为产物：
  描述：

  2-溴嘧啶 、 三甲基乙炔基硅 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 作用下， 以 乙腈 为溶剂， 以92 %的产率得到2-三甲基锡乙炔嘧啶
  参考文献：
  名称：

  Stretching the Bisalkyne Raman Spectral Palette Reveals a New Electrophilic Covalent Motif

  摘要：

  摘要 为多路生物正交拉曼成像设计了具有不同振动频率和生理相关 cLog P 的小型杂芳基二炔（Het-DY）标签。结果表明，Pd-Cu 催化耦合与 Lei 配体的使用相结合，提高了所需的异质耦合 Het-DY 标签的总产量，最大限度地减少了同质副产物的产生。光谱数据与 DFT 计算预测的趋势一致，系统引入的富电子/贫电子环拉伸了芳基封端二炔的频率极限（2209-2243 cm-1）。在细胞摄取研究中，这些 Het-DY 标签的扩散分布明显改善了对数 P 值，而用细胞器标记物对标签进行功能化，则可以获得特定位置的生物图像。基于 LC-MS 和 NMR 的分析表明，一些杂芳基封端的内部炔烃是潜在的亲核陷阱，其反应活性取决于结构。这些具有共价反应性的生物相容性 Het-DY 标签为拉曼生物正交成像开辟了新途径。

  DOI：

  10.1002/chem.202300953

文献信息

• Enhanced triple-helix and double-helix formation with oligomers
  申请人：Gilead Sciences, Inc.

  公开号：US05645985A1

  公开（公告）日：1997-07-08

  Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used used for diagnostic purposes in order to detect viruses or disease conditions.

  揭示了一种新型寡聚体，相对于仅含有传统碱基的寡聚体，具有更强的形成双链或三链的能力。这些寡聚体包含碱基5-(1-丙炔基)尿嘧啶，5-(1-丙炔基)胞嘧啶或相关类似物。本发明的寡聚体能够（i）与各种目标序列如病毒或癌基因序列形成三链，通过在生理pH下耦合到目标DNA双链的主沟；或者（ii）通过结合到单链DNA或由目标基因编码的RNA而形成双链。本发明的寡聚体可以构建成具有任何所需序列，只要该序列通常包括一个或多个被本发明类似物替代的碱基。本发明的组合物可用于诊断目的，以便检测病毒或疾病情况。
• [EN] PYRAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE
  申请人：HUA MEDICINE (SHANGHAI) LTD

  公开号：WO2017117708A1

  公开（公告）日：2017-07-13

  Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

  本文提供了公式I的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗或预防mGluR5介导的疾病非常有用，例如急性和/或慢性神经系统疾病、认知障碍和记忆缺陷，以及急性和慢性疼痛。
• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2016113335A1

  公开（公告）日：2016-07-21

  The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及一种通式（1）的化合物。通式（1）的化合物适用于治疗与在哺乳动物（如人类）中的一个半乳凝集素（例如半乳凝集素-3）与配体结合有关的疾病的方法。此外，本发明涉及一种治疗与在哺乳动物（如人类）中的一个半乳凝集素（例如半乳凝集素-3）与配体结合有关的疾病的方法。
• Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors
  作者：A. Keeley、P. Ábrányi-Balogh、G. M. Keserű

  DOI：10.1039/c8md00327k

  日期：——

  A fragment library of electrophilic small heterocycles was characterized through cysteine-reactivity and aqueous stability tests that suggested their potential as covalent warheads.

  通过半胱氨酸反应性和水稳定性测试，对亲电性小杂环片段库进行了表征，结果表明它们有潜力作为共价战斗头。
• Unravelling the Mechanism of Excited-State Interligand Energy Transfer and the Engineering of Dual Emission in [Ir(C^∧N)₂(N^∧N)]⁺ Complexes
  作者：Paul A. Scattergood、Anna M. Ranieri、Luke Charalambou、Adrian Comia、Daniel A. W. Ross、Craig R. Rice、Samantha J. O. Hardman、Jean-Louis Heully、Isabelle M. Dixon、Massimiliano Massi、Fabienne Alary、Paul I. P. Elliott

  DOI：10.1021/acs.inorgchem.9b03003

  日期：2020.2.3

  triplet-excited-state interligand energy transfer dynamics and the origin of dual emission for phosphorescent iridium(III) complexes are presented. The complexes [Ir(C∧N)2(N∧N)]+ (HC∧N = 2-phenylpyridine (1a-c), 2-(2,4-difluorophenyl)pyridine (2a-c), 1-benzyl-4-phenyl-1,2,3-triazole (3a-c); N∧N = 1-benzyl-4-(pyrid-2-yl)-1,2,3-triazole (pytz, a), 1-benzyl-4-(pyrimidin-2-yl)-1,2,3-triazole (pymtz, b), 1-benz

  提出了有关三重态激发态配体能量转移动力学机制以及磷光铱（III）络合物双重发射起源的基本见解。配合物[Ir（C∧N）2（N∧N）] +（HC∧N= 2-苯基吡啶（1a-c），2-（2,4-二氟苯基）吡啶（2a-c），1-苄基-4-苯基-1,2,3-三唑（3a-c）; N = N = 1-苄基-4-（吡啶-2-基）-1,2,3-三唑（pytz，a），1 -苄基-4-（嘧啶-2-基）-1,2,3-三唑（pymtz，b），1-苄基-4-（吡嗪-2-基）-1,2,3-三唑（pyztz， c））在室温流体溶液中由三重态金属到配体的电荷转移（3MLCT）状态与以配体为中心的（3LC）（1a，2a和2b）或配体到配体的电荷转移（ 3LL'CT）字符（1c，2c和3a-c）。特别令人惊奇的是，基于嘧啶的络合物1b在3MLCT / 3LC和3MLCT / 3LL'CT状态下均呈现双重发射。在77 K时，1b的光致发光光谱中丢失了3MLCT